Abstract��OBJECTIVE To discuss the mode of grading pharmaceutical care on patients with asthma and chronic obstructive pulmonary disease (COPD). METHODS Combined with guidelines on patients with asthma and COPD, ,the standards for grading pharmaceutical services were formulated. Two hundred and fifth-six patients are divided into intervention group and control group. And patients were given different levels of pharmaceutical services with grading standard. Before the intervention, 3 months and 6 months after intervention, grading score, medication compliance and lung function index (FEV1/ FVC, FEV1% value) were expected to make the comparison between the two groups. The incidence of adverse reactions, the number of exacerbations greater than or equal to 2 times and clinical control rate were observed. RESULTS Compared with control group, 6 months after intervention, the proportion of first intervention decreased by 25%, the incidence of adverse reactions decreased by 7.82%, the number of exacerbations greater than or equal to 2 times was reduced by 7.81%, the rate of clinical effective increased by 23.43%, FEV1/FVC, FEV1% value and medication adherence has improved significantly (P<0.05). CONCLUSION The grading pharmaceutical care for patients with asthma and COPD, can help pharmacists find the crucial guardianship objects in the shortest time, and improve the quality of pharmaceutical care and clinical effect.
����,����,����,������,������. ���������������Էμ������߷ּ�ҩѧ�����ʵʩ���ٴ�����[J]. �й�ҩѧ��־, 2017, 52(16): 1460-1464.
QIN Qiong, CHEN Rong, ZHANG Yan, BAO Jian-an, MIAO Li-yan. Clinical Evaluation and Implement of Grading Pharmaceutical Care on Patients with Asthma and COPD. Chinese Pharmaceutical Journal, 2017, 52(16): 1460-1464.
The Chinese medical association respiratory neurology of asthma group. The bronchial asthma bronchial asthma prevention guide [J]. Chin J Tuberc Respir Dis(�л���˺ͺ�����־), 2016, 39(9): 675-697.
[2]
YUAN H L,YAN X,ZHOU S Q. Education practice of chronic airway disease patients using inhalant medicine [J]. Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2013, 33(22):1886-1889.
[3]
PO Y S, XU Y G, CHEN F, et al. Study on development and implementation of grading pharmaceutical care[J]. Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2015, 35(24):2163-2165.
[4]
WANG C G, CHEN F, ZHU L Q. One case of grading pharmaceutical care for allergic bronchial lung QuYin disease [J]. Tianjin Pharm(���ҩѧ), 2015, 27(6):42-44.
[5]
The Chinese medical association respiratory neurology of COPD group.��The prevention and treatment of COPD guide�� The definition, diagnosis, treatment and management of COPD[J]. Chin J Tuberc Respir Dis(�л���˺ͺ�����־), 2011, 31(3):177-185.
[6]
NATHAN R A, SORKNESS C A, KOSINSKI M, et al. Development of the asthma control test: a survey for assessing asthma control[J]. J Allergy Clin Immunol, 2004, 113(1):59-65.
[7]
CHAI J J, LIU T, CAI B Q. Evaluation of clinical signifficance of chronic obstructive pulmonary disease assessment test[J]. Chin J Tuberc Respir Dis(�л���˺ͺ�����־), 2011, 34(4):256-258.
[8]
MORIKSY D E, ANG A, KROUSEL-WOOD M, et al. Predictive validity of a medication adherence measure for hypertension control[J]. J Clin Hypertens, 2008, 10(5):348-354.
[9]
LIU T, CAI B Q. A new health quality of life questionnaire chronic obstructive pulmonary disease assessment test [J]. Acta Acad Med Sine(�й�ҽѧ��ѧԺѧ��), 2010, 32(2):234-238.
[10]
CHEN H Z, LIN G W. Practical Internal Medicine (ʵ���ڿ�ѧ)(��)[M]. 13rd ed. Beijing:People��s Medical Publishing House, 2009:15977.
[11]
Minutes of second national chronic obstructive pulmonary disease and the eighth national cor pulmonale academic meeting [J]. Chin J Tuberc Respir Dis(�л���˺ͺ�����־), 2002, 25(8):503-505.
[12]
XING J, HUANG S P, ZHANG J, et al. The pharmaceutical care on patient with chronic obstructive pulmonary disease combined bronchial asthma[J]. Tianjin Pharm(���ҩѧ), 2013, 25(1):31-34.
[13]
KIRI V A, SORIANO J, VISICK G, et al. Recent trends in lung cancer and its association with COPD:an analysis using the UK GP research database[J]. Prim Care Respir J, 2010, 19(1):57-61.
[14]
WANG Z J.Influence factors and intervention measures of medication compliance on patient with asthma.[J]. Herald Med(ҽҩ����), 2009, 28(12):1644-1646.
[15]
ANON. Global Strategy for Asthma Management and Prevention: update 2016 [DB/OL].Global Initiative for Asthma, (2016-04). (Http://www.ginaasthma.org/).
[16]
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2016)[EB/OL]. (2016-01) [2016-04-05]. http://www.goldcopd.org.
[17]
QIN Q, CHEN R, LEI W, et al. Evaluation and analysis of inhaler drug device adherence in asthma and COPD patients[J]. Chin Pharm J(�й�ҩѧ��־), 2016, 51(5):413-416.
[18]
QIN Q, SONG W H, LEI W, et al. Economic and device adherence evaluation of different doses of budesonide and formoterol inhaling on patients with asthma[J]. Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2016, 36(24): 2202-2205.
2017, Vol. 52 
